Atlas Trials

Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

Clinical trial NCT04854928 · UNKNOWN

Trial details

NCT number
NCT04854928
Sponsor
Pharma Holdings AS
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2021-05-03
Primary completion
2022-02-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.